Insider · CIK 0001578200

Schenkein David P

Reports to the SEC for 6 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001578200

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-05	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+75K sh	—	—	75,000
2026-06-03	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+6,408 sh	—	—	21,665
2026-06-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+19.2K sh	—	—	19,226
2026-01-02	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+155 sh	—	—	603
2026-01-02	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+1,962 sh	—	—	1,962
2025-08-01	PRMEPrime Medicine, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−39.1K sh	—	—	0
2025-08-01	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+39.1K sh	—	—	39,062
2025-08-01	PRMEPrime Medicine, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−45K sh	—	—	0
2025-08-01	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	45,000
2025-06-04	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+55K sh	—	—	55,000
2025-06-03	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+6,037 sh	—	—	15,257
2025-06-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+18.1K sh	—	—	18,111
2025-01-02	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+166 sh	—	—	448
2025-01-02	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+1,958 sh	—	—	1,958
2024-11-11	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director	MExercise/Conversion	+47.2K sh	$18.00	+$849K	68,661
2024-11-11	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−27.1K sh	$32.09	−$871K	41,532
2024-11-11	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−32.3K sh	$32.87	−$1.06M	9,220
2024-11-11	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−47.2K sh	—	—	0
2024-06-20	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director	AAward	+2,120 sh	—	—	2,120
2024-06-20	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+11.8K sh	—	—	11,774
2024-06-13	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,388 sh	—	—	126,242
2024-06-13	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−3,388 sh	—	—	0
2024-06-12	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	45,000
2024-05-31	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+5,967 sh	—	—	21,496
2024-05-31	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.9K sh	—	—	17,901
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+11.9K sh	$31.64	+$375K	134,712
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−11.9K sh	$33.60	−$398K	122,854
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+57.5K sh	$31.64	+$1.82M	180,325
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−57.5K sh	$34.89	−$2.01M	122,854
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−11.9K sh	—	—	57,471
2024-02-27	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−57.5K sh	—	—	0
2024-02-26	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+20.4K sh	$31.64	+$646K	143,265
2024-02-26	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−20.4K sh	$33.19	−$677K	122,854
2024-02-26	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−20.4K sh	—	—	69,329
2024-02-23	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+47.7K sh	$31.64	+$1.51M	170,585
2024-02-23	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−47.7K sh	$33.05	−$1.58M	122,854
2024-02-23	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−47.7K sh	—	—	89,740
2024-01-02	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+42 sh	—	—	282
2024-01-02	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+508 sh	—	—	508
2023-09-08	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+240 sh	—	—	240
2023-09-08	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+2,739 sh	—	—	2,739
2023-06-21	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+4,975 sh	—	—	122,854
2023-06-21	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitM Exercise/Conversion	Director	MExercise/Conversion	−4,975 sh	—	—	0
2023-06-14	PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+39.1K sh	—	—	39,062
2023-06-13	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director	AAward	+3,388 sh	—	—	3,388
2023-06-13	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+19K sh	—	—	18,958
2023-06-01	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+4,216 sh	—	—	15,529
2023-06-01	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.6K sh	—	—	12,649
2023-04-03	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+16.4K sh	$9.05	+$148K	134,242
2023-04-03	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−16.4K sh	$22.85	−$374K	117,879

Recent filings

Accepted (ET)
Jun 84
Schenkein David P0001628280-26-041579
SEC(opens sec.gov)
Jun 54
Schenkein David P0001578200-26-000004
SEC(opens sec.gov)
Jan 64
Schenkein David P0001578200-26-000002
SEC(opens sec.gov)
Aug 54
Schenkein David P0001894562-25-000050
SEC(opens sec.gov)
Jun 54
Schenkein David P0001714899-25-000138
SEC(opens sec.gov)
Jun 54
Schenkein David P0001628280-25-029774
SEC(opens sec.gov)
Jan 64
Schenkein David P0001968202-25-000012
SEC(opens sec.gov)
Nov 134
Schenkein David P0001714899-24-000219
SEC(opens sec.gov)
Jun 244
Schenkein David P0001439222-24-000102
SEC(opens sec.gov)

Companies

Address

C/O PRIME MEDICINE, INC. 60 FIRST STREET

CAMBRIDGE, MA, 02141